Dasatinib

目录号：S1021 别名： BMS-354825

Molecular Weight(MW): 488.01

Dasatinib是一种新型有效的多靶点抑制剂，作用于Abl，Src和 c-Kit，在无细胞试验中IC50分别为 <1 nM，0.8 nM 和 79 nM。

规格

价格

库存

购买数量

10mM/1mL In DMSO	RMB 1142.64	现货
25mg	RMB 1224.97	现货
100mg	RMB 3039.93	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck该产品发表文献220篇：

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nat Immunol, 2018, 19(6):561-570

PubMed: 29777213 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Nat Med, 2017, 23(3):291-300

PubMed: 28191885 ( click the link to review the publication )

Nat Med, 2017, 23(12):1424-1435

PubMed: 29131160 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Cancer Cell, 2016, 29(4):563-573

PubMed: 27070703 ( click the link to review the publication )

Nat Genet, 2014, 46(2):166-70

PubMed: 24413734 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

J Exp Med, 2020, 217(2)

PubMed: 31704808 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2020, 1864(4):129507

PubMed: 31881245 ( click the link to review the publication )

Nat Neurosci, 2019, 22(5):719-728

PubMed: 30936558 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Am J Respir Crit Care Med, 2019, 101164/rccm201902-0451OC

PubMed: 31738079 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2556

PubMed: 31186408 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1515

PubMed: 30944303 ( click the link to review the publication )

J Extracell Vesicles, 2019, 9(1):1698889

PubMed: 31853340 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-2309

PubMed: 31857430 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(16):5038-5048

PubMed: 31182436 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.215939

PubMed: 31289206 ( click the link to review the publication )
Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1104

PubMed: 31585938 ( click the link to review the publication )

Mol Syst Biol, 2019, 15(3):e8323

PubMed: 30858180 ( click the link to review the publication )

Cancer Res, 2019, 79(13):3306-3319

PubMed: 31101761 ( click the link to review the publication )

Theranostics, 2019, 9(7):1952-1964

PubMed: 31037149 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Thyroid, 2019, 29(3):395-404

PubMed: 30724135 ( click the link to review the publication )

Oncogene, 2019, 38(12):2135-2150

PubMed: 30459358 ( click the link to review the publication )

Stem Cell Reports, 2019, 10.1016/j.stemcr.2019.08.005

PubMed: 31522974 ( click the link to review the publication )

Br J Cancer, 2019, 121(7):567-577

PubMed: 31474759 ( click the link to review the publication )

J Clin Med, 2019, 8(8)

PubMed: 31382448 ( click the link to review the publication )

Cancer Discov, 2019, 9(6):756-777

PubMed: 30862724 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0449

PubMed: 31744897 ( click the link to review the publication )

J Physiol, 2019, 597(6):1627-1642

PubMed: 30488437 ( click the link to review the publication )

Mol Biol Cell, 2019, 30(9):1108-1117

PubMed: 30785867 ( click the link to review the publication )

Sci Rep, 2019, 9(1):4819

PubMed: 30894630 ( click the link to review the publication )

Sci Rep, 2019, 9(1):7617

PubMed: 31110200 ( click the link to review the publication )

Sci Rep, 2019, 9(1):17171

PubMed: 31748572 ( click the link to review the publication )

Nanomaterials (Basel), 2019, 9(12)

PubMed: 31888247 ( click the link to review the publication )

J Proteome Res, 2019, 18(1):522-534

PubMed: 30540191 ( click the link to review the publication )

J Pharmacol Exp Ther, 2019, 369(3):531-545

PubMed: 30898866 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):485

PubMed: 31118072 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2019, 9:80-86

PubMed: 30771616 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2019, 84(6):1241-1256

PubMed: 31541266 ( click the link to review the publication )
PLoS One, 2019, 14(2):e0212210

PubMed: 30779812 ( click the link to review the publication )

PLoS One, 2019, 14(2):e0212860

PubMed: 30794695 ( click the link to review the publication )

Leuk Lymphoma, 2019, 60(1):189-199

PubMed: 29741440 ( click the link to review the publication )

Environ Mol Mutagen, 2019, 60(6):513-533

PubMed: 30702769 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

J Immunol Methods, 2019, 464:22-30

PubMed: 30347189 ( click the link to review the publication )

Oncotarget, 2019, 10(23):2237-2251

PubMed: 31040916 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Sci Transl Med, 2018, 10(427)

PubMed: 29437150 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1523

PubMed: 29670076 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):85

PubMed: 29925404 ( click the link to review the publication )

Oncogene, 2018, 37(16):2104-2121

PubMed: 29379163 ( click the link to review the publication )

Oncogene, 2018, 37(21):2837-2849

PubMed: 29511345 ( click the link to review the publication )

Cell Mol Life Sci, 2018, 75(22):4223-4234

PubMed: 29955905 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459283 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):183

PubMed: 30081903 ( click the link to review the publication )

EBioMedicine, 2018, 29:112-127

PubMed: 29433983 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30572654 ( click the link to review the publication )

Cell Commun Signal, 2018, 16(1):21

PubMed: 29776413 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(10):1556-1567

PubMed: 29903769 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(7)

PubMed: 30036966 ( click the link to review the publication )

Sci Rep, 2018, 8(1):5362

PubMed: 29599515 ( click the link to review the publication )
Food Chem Toxicol, 2018, 119:464-478

PubMed: 29097117 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Front Pharmacol, 2018, 9:403

PubMed: 29765318 ( click the link to review the publication )

Front Pharmacol, 2018, 9:1285

PubMed: 30473665 ( click the link to review the publication )

Int J Oncol, 2018, 52(6):2061-2068

PubMed: 29620253 ( click the link to review the publication )

Cytokine, 2018, 111:209-215

PubMed: 30176559 ( click the link to review the publication )

Cell Adh Migr, 2018, 12(3):286-298

PubMed: 28678601 ( click the link to review the publication )

Toxicol Lett, 2018, 296:39-47

PubMed: 30086328 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

FEBS Open Bio, 2018, 8(5):732-742

PubMed: 29744288 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncoscience, 2018, 5(1-2):21-38

PubMed: 29556515 ( click the link to review the publication )

Nature, 2018, 563(7730):265-269

PubMed: 30401838 ( click the link to review the publication )

Sci Transl Med, 2017, 9(374)

PubMed: 28123069 ( click the link to review the publication )

Sci Transl Med, 2017, 9(414)10

PubMed: 29093181 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(6):754-768

PubMed: 28618271 ( click the link to review the publication )

Blood, 2017, 129(11):e26-e37

PubMed: 28122742 ( click the link to review the publication )

Hepatology, 2017, 66(6):1934-1951

PubMed: 28714104 ( click the link to review the publication )

Mol Cell, 2017, 66(5):635-647

PubMed: 28575659 ( click the link to review the publication )

Nat Commun, 2017, 8:14073

PubMed: 28102225 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(23):7360-7374

PubMed: 28939749 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):118

PubMed: 28606127 ( click the link to review the publication )

Cell Death Dis, 2017, 8(8):e3029

PubMed: 29048432 ( click the link to review the publication )
Mol Cancer Ther, 2017, 16(11):2387-2398

PubMed: 28775147 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1729-1738

PubMed: 28619758 ( click the link to review the publication )

Neoplasia, 2017, 19(4):354-363

PubMed: 28319809 ( click the link to review the publication )

Toxicol Sci, 2017, 162(1):146-166

PubMed: 29106658 ( click the link to review the publication )

J Biol Chem, 2017, 292(35):14381-14390

PubMed: 28684419 ( click the link to review the publication )

Cancer Med, 2017, 6(4):809-818

PubMed: 28316141 ( click the link to review the publication )

Clin Res Hepatol Gastroenterol, 2017, 41(6):677-686

PubMed: 28578938 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:73-83

PubMed: 28123301 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(8):1903-1913

PubMed: 27931141 ( click the link to review the publication )

J Neurophysiol, 2017, 118(1):595-609

PubMed: 28446585 ( click the link to review the publication )

Eur J Haematol, 2017, 99(5):442-448

PubMed: 28881484 ( click the link to review the publication )

Arch Pharm Res, 2017, 40(2):197-203

PubMed: 27988882 ( click the link to review the publication )

Mol Vis, 2017, 23:823-831

PubMed: 29225458 ( click the link to review the publication )

Ther Drug Monit, 2017, 39(3):252-262

PubMed: 28490048 ( click the link to review the publication )

Oncotarget, 2017, 8(47):81794-81802

PubMed: 29137222 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90262-90277

PubMed: 29163826 ( click the link to review the publication )

Oncotarget, 2017, 8(43):73871-73883

PubMed: 29088753 ( click the link to review the publication )

Nat Commun, 2016, 7:10060

PubMed: 26725982 ( click the link to review the publication )

Nat Commun, 2016, 7:11889

PubMed: 27297662 ( click the link to review the publication )

Nat Commun, 2016, 7:12428

PubMed: 27687249 ( click the link to review the publication )

Leukemia, 2016, 30(6):1273-81

PubMed: 26987906 ( click the link to review the publication )

Leukemia, 2016, 30(7):1493-501

PubMed: 27044711 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(51):E8228-E8237

PubMed: 27930322 ( click the link to review the publication )

Cancer Res, 2016, 76(12):3520-30

PubMed: 27197167 ( click the link to review the publication )
Int J Cancer, 2016, 139(10):2359-69

PubMed: 27434411 ( click the link to review the publication )

Cancer Lett, 2016, 376(1):188-96

PubMed: 26996299 ( click the link to review the publication )

Breast Cancer Res, 2016, 18(1):80

PubMed: 27495374 ( click the link to review the publication )

Development, 2016, 143(10):1674-87

PubMed: 26989177 ( click the link to review the publication )

J Infect Dis, 2016, 213(11):1767-76

PubMed: 26802142 ( click the link to review the publication )

Stem Cells Int, 2016, 2016:9601493

PubMed: 26788073 ( click the link to review the publication )

BMC Cancer, 2016, 16:229

PubMed: 26984511 ( click the link to review the publication )

J Gen Virol, 2016, 97(5):1134-1144

PubMed: 26879209 ( click the link to review the publication )

Oncol Lett, 2016, 12(5):3598-3608

PubMed: 27900042 ( click the link to review the publication )

Assay Drug Dev Technol, 2016, 14(7):395-406

PubMed: 27552144 ( click the link to review the publication )

Oncotarget, 2016, 7(47):78083-78094

PubMed: 27801667 ( click the link to review the publication )

Oncotarget, 2016, 7(37):59236-59244

PubMed: 27494860 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Sci Transl Med, 2015, 7(284):284ra57

PubMed: 25904741 ( click the link to review the publication )

Blood, 2015, 125(8):1282-91

PubMed: 25515960 ( click the link to review the publication )

Leukemia, 2015, 29(3):586-597

PubMed: 25134459 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.02.044

PubMed: 25737303 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1767

PubMed: 25996294 ( click the link to review the publication )

Radiother Oncol, 2015, 116(3):431-7

PubMed: 26320552 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(1):262-8

PubMed: ( click the link to review the publication )

Eur Neuropsychopharmacol, 2015, 25(8):1275-86

PubMed: 25983018 ( click the link to review the publication )

J Cell Sci, 2015, 128(2):251-65

PubMed: ( click the link to review the publication )

J Virol, 2015, 90(4):1918-30

PubMed: 26656684 ( click the link to review the publication )

Eur Neuropsychopharm, 2015, 10.1016/j.euroneuro.2015.04.021

PubMed: ( click the link to review the publication )
Clin Immunol, 2015, 157(2):205-215

PubMed: 25728491 ( click the link to review the publication )

Eur J Pharm Sci, 2015, 80:56-65

PubMed: 26296860 ( click the link to review the publication )

Neurotox Res, 2015, 27(4):384-98

PubMed: 25782580 ( click the link to review the publication )

Arch Biochem Biophys, 2015, 10.1016/j.taap.2015.03.018

PubMed: 25843419 ( click the link to review the publication )

PLoS One, 2015, 10(6):e0129663

PubMed: 26061184 ( click the link to review the publication )

Pulm Pharmacol Ther, 2015, 10.1016/j.pupt.2015.03.001

PubMed: 25843005 ( click the link to review the publication )

Leuk Res, 2015, 10.1016/j.leukres.2015.08.007

PubMed: 26346348 ( click the link to review the publication )

Mol Med Rep, 2015, 12(3):3249-3256

PubMed: 25975261 ( click the link to review the publication )

Int J Clin Exp Pathol, 2015, 8(7):7818-24

PubMed: 26339346 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: 25269544 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(4):557-62

PubMed: 25712742 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 6(14):12405-20

PubMed: 25915159 ( click the link to review the publication )

Oncotarget, 2015, 6(4):1967-80

PubMed: 25596742 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncotarget, 2015, 6(36):38854-65

PubMed: 26513174 ( click the link to review the publication )

Blood, 2014, 123(21):3296-304

PubMed: 24723681 ( click the link to review the publication )

Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Leukemia, 2014, 28(10):2109-12

PubMed: 24919804 ( click the link to review the publication )

Cell Rep, 2014, 8(4):1037-48

PubMed: 25127139 ( click the link to review the publication )

Elife, 2014, 3:e02523

PubMed: 24844246 ( click the link to review the publication )

Cancer Lett, 2014, 344(1):90-100

PubMed: 24513268 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1023

PubMed: 24457967 ( click the link to review the publication )

Cell Death Dis, 2014, 6:e1595

PubMed: 25590805 ( click the link to review the publication )
J Cell Sci, 2014, 127(Pt 14):3039-51

PubMed: 24928894 ( click the link to review the publication )

Int J Mol Sci, 2014, 15(4):5838-51

PubMed: 24714091 ( click the link to review the publication )

Exp Cell Res, 2014, 328(1):20-31

PubMed: 25128812 ( click the link to review the publication )

J Pharm Biomed Anal, 2014, 94:125-31

PubMed: 24561338 ( click the link to review the publication )

PLoS One, 2014, 9(9):e107367

PubMed: 25198091 ( click the link to review the publication )

PLoS One, 2014, 9(1):e85485

PubMed: 24427313 ( click the link to review the publication )

Mol Biosyst, 2014, 10.1039/C4MB00224E

PubMed: 25099472 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Leuk Lymphoma, 2014, 10.3109/10428194.2014.898759

PubMed: 24597981 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Head Neck, 2014, 36(3):375-84

PubMed: 23729178 ( click the link to review the publication )

Graefes Arch Clin Exp Ophthalmol, 2014, 10.1007/s00417-014-2674-7

PubMed: 24874745 ( click the link to review the publication )

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420 ( click the link to review the publication )

Oncoscience, 2014, 1(1):57-68

PubMed: 25593988 ( click the link to review the publication )

J Exp Med, 2013, 210(11):2205-21

PubMed: 24127489 ( click the link to review the publication )

J Exp Med, 2013, 210(12):2569-82

PubMed: 24190431 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(18):5053-67

PubMed: 23900136 ( click the link to review the publication )

PLoS Biol, 2013, 11(3):e1001515

PubMed: 23526884 ( click the link to review the publication )

Cancer Lett, 2013, 340(1):43-50

PubMed: 23811285 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 26(4):518-26

PubMed: 23582185 ( click the link to review the publication )

Neoplasia, 2013, 15(11):1272-81

PubMed: 24339739 ( click the link to review the publication )

J Thorac Cardiovasc Surg, 2013, 145(2):531-8

PubMed: 23142123 ( click the link to review the publication )

J Neurochem, 2013, 12(12):2864-73

PubMed: 24130049 ( click the link to review the publication )
J Biol Chem, 2013, 288(8):5553-61

PubMed: 23303179 ( click the link to review the publication )

Int J Oncol, 2013, 43(6):2064-72

PubMed: 24126464 ( click the link to review the publication )

Cell Cycle, 2013, 12(18):2978-91

PubMed: 23974111 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 72(1):35-44

PubMed: 23712327 ( click the link to review the publication )

Pharmgenomics Pers Med, 2013, 6:63-72

PubMed: 24019750 ( click the link to review the publication )

Sci Rep, 2013, 3:2100

PubMed: 23812503 ( click the link to review the publication )

Sci Transl Med, 2012, 4(136):136ra70

PubMed: 22649091 ( click the link to review the publication )

Blood, 2012, 119(21):4981-91

PubMed: 22411867 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(1):127-39

PubMed: 22090359 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(17):6584-10

PubMed: 22492965 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Br J Haematol, 2012, 157(4):510-4

PubMed: 22313359 ( click the link to review the publication )

J Virol, 2012, 86(16):8765-72

PubMed: 22696643 ( click the link to review the publication )

Angiogenesis, 2012, 15(1):33-45

PubMed: 22203239 ( click the link to review the publication )

Cancer Immunol Immun, 2012, 61(2):193-202

PubMed: 21874302 ( click the link to review the publication )

Invest New Drugs, 2012, 30(1):417-22

PubMed: 20953816 ( click the link to review the publication )

Stem Cells Dev, 2012, 21(16):2939-48

PubMed: 22642671 ( click the link to review the publication )

Hematol Oncol, 2012, 31(3):156-63

PubMed: 23108877 ( click the link to review the publication )

PLoS One, 2012, 7(7):e40853

PubMed: 22815843 ( click the link to review the publication )

J Biomol Screen, 2012, 18(4):388-99

PubMed: 23134735 ( click the link to review the publication )

J Liq Chromatogr R T, 2012, 2503-2510

PubMed: ( click the link to review the publication )

Cell Res, 2011, 21(7):1080-7

PubMed: 21423276 ( click the link to review the publication )

J Mol Biol, 2011, 411(2):474-85

PubMed: 21699901 ( click the link to review the publication )

J Virol, 2011, 85(5):2296-303

PubMed: 21177802 ( click the link to review the publication )
Cancer Prev Res , 2011, 4(8):1222-32

PubMed: 21546539 ( click the link to review the publication )

J Biol Chem, 2011, 286(16):13846-51

PubMed: 21343293 ( click the link to review the publication )

Exp Hematol, 2011, 39(8):859-65.e2

PubMed: 21689725 ( click the link to review the publication )

PLoS One, 2010, 5(11):e14143

PubMed: 21152443 ( click the link to review the publication )

产品安全说明书

Src抑制剂选择性比较

生物活性

产品描述

Dasatinib是一种新型有效的多靶点抑制剂，作用于Abl，Src和 c-Kit，在无细胞试验中IC50分别为 <1 nM，0.8 nM 和 79 nM。

靶点

Abl ^[1] (Cell-free assay)	Src ^[1] (Cell-free assay)	c-Kit (D816V) ^[2] (Cell-free assay)	c-Kit (wt) ^[2] (Cell-free assay)
0.6 nM	0.8 nM	37 nM	79 nM

体外研究

在抑制表达野生型Bcr-Abl或全部Bcr-Abl突变型（除了T315I）的Ba/F3增殖时，Dasatinib效果比Imatinib高很多。与Imatinib相比，Dasatinib呈2倍指数增长效力(约325倍)。Dasatinib有效抑制野生型Abl 激酶和全部突变型（除了T315I）。Dasatinib 直接靶向作用于野生型和突变型Abl激酶域，且抑制自磷酸化和底物磷酸化，这种作用存在浓度依赖性。Dasatinib作用于表达野生型 Bcr-Abl的细胞时，效果比Imatinib高325倍多。^[1] TgE骨髓细胞菌落百分数从未处理孔的100% 降低到Dasatinib处理孔的4.12%。有 Dasatinib存在时, WT 和TgE骨髓细胞形成的菌落百分数明显不同。LMP2A的表达可促进 B 淋巴细胞存活和增殖，而Dasatinib通过靶向作用于Lyn 和/或c-Abl 激酶可抑制以上存活和增殖。^[2] Dasatinib 处理一系列甲状腺癌细胞，抑制Src信号, 降低生长速度,使细胞周期停滞，且诱导凋亡。使用剂量不断增加的 Dasatinib (0.019 μM 到 1.25 μM) 处理C643, TPC1, BCPAP, 和 SW1736 细胞3天，抑制50%细胞生长，然而抑制K1细胞系生长则需更高浓度Dasatinib。使用10 nM 或50 nM Dasatinib 处理BCPAP，SW1736 和 K1 细胞，导致G1期细胞提高9-22%，而S期细胞百分数则降低7-18%。^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
M07ep210	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2HpSVczKGh?	MnvJSG1UVw>?	MkfxTWM2OD1yLkCwNFA4KM7:TR?=	NUDZSpB1OTd7NU[wPFA>
K562	M{XRXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEXEOZk4OiCq	M2f3cWROW09?	NYnvN4JuUUN3ME2wMlAxOSEQvF2=	MVOxO\|k2PjB6MB?=
M07e	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWnXSHlqPzJiaB?=	MYPEUXNQ	Mo\DTWM2OD1yLkCwNVIh\|ryP	NWKwVop1OTd7NU[wPFA>
ALL3	MXTDfZRwfG:6aXOgRZN{[Xl?	NXH4O\|RXOC5zzszN	Mn7oO\|IhcA>?	MnTwSG1UVw>?	MojmTWM2OD1yLkCwNFQh\|ryP	NXjhcXBHOTl6OEm1OFA>
CML	NWXyZZNYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGP4fHAzOCCvaX6=	NEHib4lFVVOR	NH7jPYdKSzVyPUCuNFAyKM7:TR?=	MnTQNVkzOTlyMU[=
BA/F3	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NELZOZY4OiCq	NUHxcHplTE2VTx?=	MnfpTWM2OD14LkW4PUDPxE1?	MVGyN\|A5QDZ2NB?=
BA/F3	M17tUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3LOVlczKGh?	NWjVW5pwTE2VTx?=	NVe0bVBPUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBOOzVzVDDteZRidnRid3n0bEBKSzVyIH;mJFAvODByOEROwG0>	M4TBblI{ODh6NkS0
BA/F3	Ml;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NI\5bWo4OiCq	MXfEUXNQ	MUPJcoR2[2W\|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzD3bYxlKHS7cHWgRoNzNUGkbDD3bZRpKEmFNUCgc4YhOC5yMES1{txO	NVv5ZlJTOjNyOEi2OFQ>
BA/F3	MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYnxU\|c3PzJiaB?=	NULWc3F1TE2VTx?=	MkDQTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy\|IHX4dJJme3OrbnegRoNzNUGkbDDUN\|E2USCvdYThcpQhf2m2aDDJR\|UxKG:oIEGuO\|E1\|ryP	NUnidZpjOjNyOEi2OFQ>
BA/F3	NF\PZmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXi3NkBp	NX;o[YVuTE2VTx?=	MnnxTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTjR6NmOgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNFnPxE1?	NFHMS5YzOzNyMUewNy=>
BA/F3	NIDz[GhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3PFRlczKGh?	MlniSG1UVw>?	MWHJcoR2[2W\|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBGOjV3SzDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECzNu69VQ>?	M4LpdlI{OzBzN{Cz
BA/F3	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmjmO\|IhcA>?	M{m3cGROW09?	NIjvT5JKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCJMkWwSUBufXSjboSgZZN{\XO\|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR\|UxKG:oIECuNFA2Oc7:TR?=	MVmyN\|MxOTdyMx?=
BA/F3	MlHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFPhZ3g4OiCq	MYrEUXNQ	NWXMRZR[UW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiUUK1NmghdXW2YX70JIF{e2W\|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxQM7:TR?=	M1X4ZlI{OzBzN{Cz
BA/F3	M3rMeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnyzO\|IhcA>?	NXXRNldZTE2VTx?=	NEfxN5NKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHM{W5WkBufXSjboSgZZN{\XO\|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR\|UxKG:oIECuNFAyO87:TR?=	M3y0[FI{OzBzN{Cz
BA/F3	M1W5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MW[3NkBp	NUj6d5dMTE2VTx?=	NV;SNJBjUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIIfpcIQhfHmyZTDCR3IuSUKOIHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNVnPxE1?	NUHQToM5OjN\|MEG3NFM>
BA/F3	NXrUXIp6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M17DUVczKGh?	Mnv6SG1UVw>?	MXrJcoR2[2W\|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEB[OjV\|SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECyN:69VQ>?	MUiyN\|MxOTdyMx?=
BA/F3	NVnwbYtLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoPJO\|IhcA>?	NVPxcFhuTE2VTx?=	MkmxTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhXDNzNVmgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iB\|LkdOwG0>	M4nwTlI{OzBzN{Cz
BA/F3	NXi4do1wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWm3NkBp	MmTPSG1UVw>?	Moj6TY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghUW6qaXLpeIlwdiC5aYToJGlEPTBib3[gNk42\|ryP	NX\zd5hzOjN\|MEG3NFM>
T cell	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnzhO\|IhcA>?	MXLEUXNQ	MWTJcohq[mm2czDhcpRqKEOGMz2gZY5lKGGwdHmgR2QzQC2rbnT1Z4VlKFRiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjByM988US=>	M4j6eFE4OTV2NUGy
WiDr	M2HuRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVLQcYU{PzJiaB?=	NHP4dVhFVVOR	Mo\QTWM2OD1yLkC1NkDPxE1?	NIHqbW8yPTZzNUWxNi=>
PC3	NGSwXmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlLhO\|IhcA>?	MoTuSG1UVw>?	NYjpR5ZmUUN3ME2wMlAxQTRizszN	M{jXeFE2PjF3NUGy
MDA-MB-231	M3PYdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWq1[pQzPzJiaB?=	NFW4eGlFVVOR	MlrkTWM2OD1yLkCxNkDPxE1?	NVnaSlJmOTV4MUW1NVI>
Hs578T	NIrlV5NEgXSxdH;4bYMhSXO\|YYm=		MmfPO\|IhcA>?	NWfRcZA6TE2VTx?=	M1Xae2dKPTB;MD6wN{DPxE1?	NIjNfVEzPDBzNUOyOy=>
HMEC	NXfIXHZ3S3m2b4TvfIlkKEG\|c3H5		MWm3NkBp	MoD5SG1UVw>?	MVHHTVUxRTFwODFOwG0>	M33PR\|I1ODF3M{K3
DU145	NXzZVFF6S3m2b4TvfIlkKEG\|c3H5		M1vsXVczKGh?	MnT5SG1UVw>?	M1nnZmdKPTB;MD6xOkDPxE1?	NVHoT5VUOjRyMUWzNlc>
U251	M1vEdWN6fG:2b4jpZ{BCe3OjeR?=		M{n0XFczKGh?	MkG5SG1UVw>?	NUXvT\|V2T0l3ME2yMlgyKM7:TR?=	MoHxNlQxOTV\|Mke=
NCI60	MUfDfZRwfG:6aXOgRZN{[Xl?		NYDnOplEPzJiaB?=	NV21N3hjTE2VTx?=	MoD3S2k2OD13Lkeg{txO	NVTYNZpoOjRyMUWzNlc>
MALME-3M	MojLR5l1d3SxeHnjJGF{e2G7		M1u0W\|czKGh?	NUPN[FBYTE2VTx?=	NEHXXGZIUTVyPU[uOlEh\|ryP	M2HKNVI1ODF3M{K3
KM12	NITUeY9EgXSxdH;4bYMhSXO\|YYm=		MXG3NkBp	NYG1XXBYTE2VTx?=	NXW4ZpFVT0l3ME23MlQ1KM7:TR?=	MoHTNlQxOTV\|Mke=
SW620	M1\VVWN6fG:2b4jpZ{BCe3OjeR?=		Ml\lO\|IhcA>?	NH[zfGtFVVOR	MYfHTVUxRThwNEOg{txO	MY[yOFAyPTN{Nx?=
RXF 393NL	MmT5R5l1d3SxeHnjJGF{e2G7		NGnsXII1KGSjeYO=	MUDEUXNQ	MVrJR\|UxRTBwMEKxO{DPxE1?	NX;JdpVrOjN{NUOwO\|Q>
LXFA 983L	M3y4TmN6fG:2b4jpZ{BCe3OjeR?=		NXnGPVdZPCCmYYnz	NXHzTZhLTE2VTx?=	Mo\aTWM2OD1yLkC1OlUh\|ryP	NUHyd21LOjN{NUOwO\|Q>
PRXF DU145	NVvFS3dwS3m2b4TvfIlkKEG\|c3H5		NHLVd4k1KGSjeYO=	M{X5d2ROW09?	MXLJR\|UxRTBwME[yN{DPxE1?	NWTFSGliOjN{NUOwO\|Q>
PAXF 1657L	M2fFXGN6fG:2b4jpZ{BCe3OjeR?=		NGrnVJY1KGSjeYO=	MUPEUXNQ	NHHyZ\|ZKSzVyPUCuNVIyKM7:TR?=	MlXXNlMzPTNyN{S=
CXF 1103L	M1:yWmN6fG:2b4jpZ{BCe3OjeR?=		NXzOcWJUPCCmYYnz	M3\6UWROW09?	MVfJR\|UxRTRwM{[g{txO	MlnaNlMzPTNyN{S=
GXF251L	NXXRSI53S3m2b4TvfIlkKEG\|c3H5		NWTMPXh{PCCmYYnz	M{PtV2ROW09?	MUDJR\|UxRTJwMkWg{txO	M3jHOVI{OjV\|MEe0
NCI-H23	NFr5N5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHr3Ulg4OiCq	Mof1SG1UVw>?	MXPJR\|UxRTJwMkeg{txO	MkfhNlM2OjFyMkC=
HCT116	NY\hc4lOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVnpd29OPzJiaB?=	MYfEUXNQ	NUfXc2ZnUUN3ME2yMlMh\|ryP	Mke1NlM2OjFyMkC=
MCF7	NYi2UldbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYO3NkBp	NHvBN\|BFVVOR	M1vtTWlEPTB;Mj61O{DPxE1?	M2e3cFI{PTJzMEKw
NCI-H460	M1f3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXW3NkBp	NG\XdHZFVVOR	Mmm0TWM2OD16Lkm5JO69VQ>?	NXL2V3NkOjN3MkGwNlA>
DLD1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGXSR\|Q4OiCq	M3vUVmROW09?	M1ntSWlEPTB;ND62JO69VQ>?	NIrmUJgzOzV4N{m2NC=>
NCI-H661	M4LudGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFn2O5Y4OiCq	NWfoOHV2TE2VTx?=	Mnf1TWM2OD15Lkig{txO	NHLmfGQzOzV4N{m2NC=>
A549	NHjHTYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1jIPVczKGh?	M13V[GROW09?	MlHsTWM2OD16LkKg{txO	Mo\yNlM2Pjd7NkC=
U937	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUS3NkBp	M2T6RWROW09?	Ml7HTWM2OD1zMj6yJO69VQ>?	NHrZb\|gzOzV4N{m2NC=>
HEK293	MW\GeY5kfGmxbjDBd5NigQ>?	M33X[VExyqEQvF2=		M2fQ[GROW09?	M4XqO2lv\HWlZYOgZolv\GmwZzDh[oZqdmm2eTD0c{BpfW2jbjDmeYxtNWynbnf0bEBJcXNvdHHn[4VlKE27dEGgb4lv[XOnIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNid3n0bEBKSzVyIH;mJFAvODZ\|zszN	MYCyNlc4ODZzMB?=
HUVEC	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTNRmFPOC5zNdMg{txO	MlvzO\|IhcA>?	Mk\4SG1UVw>?	M4nCbGlv\HWlZYOgZY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiY3:tZ5VtfHW{ZXSge4l1cCC4YYPjeYxieiC\|bX;veIghdXW\|Y3zlJINmdGy\|IHHzd4V{e2WmIHHzJGlvcGmkaYTpc44hd2ZiY3XscEBoem:5dHigZZQhOC5zNTD1US=>	NFT1eIMzOjh3M{m5Ny=>
HUVEC	MoPTSpVv[3Srb36gRZN{[Xl?	NXTUZ4F4OTYEoN88US=>	MmDNO\|IhcA>?	NXfnNFgzTE2VTx?=	NYLOUFNZUW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO\|ZXSgZZMhUW6qaXLpeIlwdiCxZjDu[ZR4d3KtIH\vdo1ifGmxbjDheEAyNjhidH:gNVUhfU1?	MlroNlI5PTN7OUO=
Plasmodium falciparum	M37vTmZ2dmO2aX;uJGF{e2G7	NV7ucGdWOTEEoN88US=>	M4rFSlE2KG2rbh?=	MWDEUXNQ	NYrNcFIxUW6qaXLpeJMhWGyjc33v[Il2dSCoYXzjbZBienWvIIDyc4xq\mW{YYTpc44h[nliaX7obYJqfGmwZzD0bIUhTnWwY4Tpc44hd2ZiUH\DSHBMOSCycn;0[YlvKHerdHigTWM2OCCxZjCxMlE4\|ryP	MoPTNlQ2PTB\|M{C=
PC3	NEjzTGFHfW6ldHnvckBCe3OjeR?=	MUiwMlEh\|ryP	NUH3bnFLPSCq	M1OwdGROW09?	Mn:wTY5pcWKrdIOgbJVu[W5iUFOzJINmdGxiYXTo[ZNqd25iYYSgNVAxKG6P	M1fJfFE6PDZ{OUe1
DU145	M4i3cGZ2dmO2aX;uJGF{e2G7	MW[wMlEh\|ryP	NWPnc5R[PSCq	NXTmRnpRTE2VTx?=	MkX2TY5pcWKrdIOgbJVu[W5iRGWxOFUh[2WubDDh[Ihme2mxbjDheEAyODBibl2=	NGTMVG4yQTR4Mkm3OS=>
PC3	NW\BWW53U2mwYYPlJGF{e2G7	M4jJNFAvOSEQvF2=	Ml3SOUBp	MkfuSG1UVw>?	NGXMVnBKdmirYnn0d{BkW3KlIHnuJIh2dWGwIGDDN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhW3KlIGm0NVYhdGW4ZXygZZQhOTByIH7N	NVLpbHBkOTl2NkK5O\|U>
DU145	MnfsT4lv[XOnIFHzd4F6	MWKwMlEh\|ryP	NUjGVpJsPSCq	NHvsb2NFVVOR	NXnvWWpQUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiU4LjJHk1OTZibHX2[Ywh[XRiMUCwJI5O	MoHINVk1PjJ7N{W=
PC3	MlvYT4lv[XOnIFHzd4F6	M4fqRlAvOSEQvF2=	NF7Md3Y2KGh?	M{XrPGROW09?	MXnJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgSmFMKFl3N{[vXVU4PyCuZY\lcEBifCBzMECgcm0>	M{XmcVE6PDZ{OUe1
DU145	MV7LbY5ie2ViQYPzZZk>	NEjXZ2IxNjFizszN	Mn:yOUBp	MYPEUXNQ	NIjPeo1KdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCIQVugXVU4Pi:\NUe3JIxmfmWuIHH0JFExOCCwTR?=	NYLzUGdVOTl2NkK5O\|U>
Huh7	NYnaO2plSW62aY\pdoFtKEG\|c3H5	NX:y[ZFGOi53IN88US=>	MVy0JIRigXN?	NXyzS5RXTE2VTx?=	MVnJcohq[mm2czD2bZJidCC\|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIh2dWGwIFj1bFch[2WubIOgZZN{\XO\|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJZqemGuIHXueoVtd3CnIIDyc5RmcW5id3n0bIlvKHCncnnueYNt\WG{IILl[4lwdiCjdDCyMlUhfU1?	MWOxO\|M3ODZ5Nh?=
C6/36	M3HxeWFvfGm4aYLhcEBCe3OjeR?=	NFPwc3ozNjVizszN	MYi0JIRigXN?	NIjYb5pFVVOR	NELwNGNKdmirYnn0d{B3cXKjbDDzdJJm[WRiaX6gSIVv\3WnII\pdpV{NWmwZnXjeIVlKGG\|aXHuJJRq\2W{IH3vd5F2cXSxIFO2M\|M3KGOnbHzzJIF{e2W\|c3XkJIF{KGGlY4XteYxifGmxbjDv[kB3cXKjbDDlcpZmdG:yZTDwdo91\WmwIIfpeIhqdiCyZYLpcpVkdGWjcjDy[Ydqd25iYYSgNk42KHWP	MXixO\|M3ODZ5Nh?=
U937	NYS0ZYJMTnWwY4Tpc44hSXO\|YYm=	MVSxJO69VQ>?	MUWxJIg>	MlHvSG1UVw>?	NWrrVIJWWmWmdXPld{Bj[XOjbDDUUmZidHCqYTDy[Yxm[XOnIHnuJIh2dWGwIGW5N\|ch[2WubIO=	NHu3dJcyPzZ6NEC5PS=>
U937	NHniZ\|RHfW6ldHnvckBCe3OjeR?=	Mn\SNUDPxE1?	M4KxZ\|EhcA>?	M3XU[2ROW09?	MXPS[YR2[2W\|IFzQV{1qdmS3Y3XkJHRPTmGucHjhJJJmdGWjc3WgbY4hcHWvYX6gWVk{PyClZXzsdy=>	MU[xO\|Y5PDB7OR?=
murine mast cell	M33xbGZ2dmO2aX;uJGF{e2G7	MWmxJO69VQ>?	M{PxTVI1KGh?	NVLueFVmTE2VTx?=	M1jEXmlvcGmkaYTzJIFvfGmpZX6tbY5lfWOnZDDJUFYhe2WlcnX0bY9vKGmwIFnnSUBxemmvZXSgcY92e2VibXHzeEBk\WyuczDheEAyKHWP	NIr4OIUyPzZ6NEC5PS=>
BV-173	MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY\uVYFiUUN3ME2wMlAxODByMEGwPUDPxE1?	M1zob3NCVkeHUh?=
K-562	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVnxUlFEUUN3ME2wMlAxODByMEK2OkDPxE1?	M2LMUHNCVkeHUh?=
BL-70	NXPFOGlDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2Ht[WlEPTB;MD6wNFAxODB6MkKg{txO	MoTxV2FPT0WU
EM-2	NF\aOVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPrS3pKSzVyPUCuNFAxODBzMEig{txO	NWDRd\|ZSW0GQR1XS
LAMA-84	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFfpfHJKSzVyPUCuNFAxODB\|MkGg{txO	NYfqUmU3W0GQR1XS
MEG-01	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3OzN2lEPTB;MD6wNFAxODl6IN88US=>	NHvJRY9USU6JRWK=
EoL-1-cell	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTBwMECwNFE{OSEQvF2=	NUXiU4JqW0GQR1XS
CTV-1	Mn7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknFTWM2OD1yLkCwNFA1ODRizszN	MkfMV2FPT0WU
TE-15	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnnzTWM2OD1yLkCwOVg6KM7:TR?=	M4ruXnNCVkeHUh?=
NOS-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1K3OGlEPTB;MD6wNFYyOyEQvF2=	M{nCbHNCVkeHUh?=
D-336MG	NIH6eJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITtcnhKSzVyPUCuNFA3OyEQvF2=	NVfqVYRpW0GQR1XS
LB1047-RCC	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTBwMEC5PFkh\|ryP	NIHKRmVUSU6JRWK=
LB996-RCC	NYf6e2lQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI\1OpVKSzVyPUCuNFA6QTFizszN	NVOxNHkxW0GQR1XS
SW982	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M13kfmlEPTB;MD6wNVEyPSEQvF2=	NULreYJ[W0GQR1XS
TK10	NVPWXYtnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHfnPY5KSzVyPUCuNFEyPzRizszN	NEO4b5pUSU6JRWK=
A704	NIe1ToJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2D0ZWlEPTB;MD6wNVQ6OSEQvF2=	MmDtV2FPT0WU
TE-8	M2PHb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4PvR2lEPTB;MD6wNVU4PiEQvF2=	M{fIWnNCVkeHUh?=
DOHH-2	NUHYbYhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzpeFhsUUN3ME2wMlAyPzF7IN88US=>	M17qcHNCVkeHUh?=
HOP-62	NVfYbHJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEOySG9KSzVyPUCuNFE5OzRizszN	M1;yXXNCVkeHUh?=
TE-12	Mln2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnxSXdKSzVyPUCuNFE5PjFizszN	NYLP[VNTW0GQR1XS
KGN	MmnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoXQTWM2OD1yLkCxPVQzKM7:TR?=	NXr1S5ozW0GQR1XS
NCI-H1648	MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4[4eWlEPTB;MD6wNlAyOSEQvF2=	NX7FbpZLW0GQR1XS
OS-RC-2	M{TNWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIDmc2tKSzVyPUCuNFIxOyEQvF2=	NEPReZFUSU6JRWK=
GB-1	NEDtVINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWL4d4ZWUUN3ME2wMlAzOTV5IN88US=>	Mnr2V2FPT0WU
RXF393	NIXZNG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnj3TWM2OD1yLkCyN\|U4KM7:TR?=	MnLsV2FPT0WU
LC-2-ad	MmHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXryNWZvUUN3ME2wMlAzPTh4IN88US=>	NHHKb29USU6JRWK=
KS-1	NEfCOZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDNTWM2OD1yLkCyO\|Mh\|ryP	NF7EVJhUSU6JRWK=
ETK-1	M1XhTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\PNWlEPTB;MD6wNlg{OiEQvF2=	MlH2V2FPT0WU
SW954	MnHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTBwMEK5Nlch\|ryP	NVXoO4lvW0GQR1XS
Becker	NFjS[ZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn3MTWM2OD1yLkCzNFA{KM7:TR?=	MmnaV2FPT0WU
MZ1-PC	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoniTWM2OD1yLkCzNVE6KM7:TR?=	MnOzV2FPT0WU
ES6	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmThTWM2OD1yLkCzNVk{KM7:TR?=	MWrTRW5ITVJ?
KURAMOCHI	NEPLToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjFTWM2OD1yLkCzOFg4KM7:TR?=	NVztZ5NGW0GQR1XS
CGTH-W-1	NHjNSnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DtbWlEPTB;MD6wN\|U1QCEQvF2=	Ml;KV2FPT0WU
VA-ES-BJ	NGS2N3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml3ITWM2OD1yLkCzPVAzKM7:TR?=	MYHTRW5ITVJ?
LXF-289	M3\4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk\CTWM2OD1yLkCzPVU3KM7:TR?=	NFTucVNUSU6JRWK=
MPP-89	MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTBwMESwOFkh\|ryP	MmT2V2FPT0WU
SW872	M{XU[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVnWbo9SUUN3ME2wMlA1OTZzIN88US=>	M1ziOHNCVkeHUh?=
SNB75	MmjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLYTWM2OD1yLkC0OFM2KM7:TR?=	MnP3V2FPT0WU
PSN1	NVfhN2xPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MorXTWM2OD1yLkC0OFc1KM7:TR?=	M2X2RXNCVkeHUh?=
LB831-BLC	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrhdI9SUUN3ME2wMlA1PjB7IN88US=>	MnfqV2FPT0WU
MFH-ino	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTBwMES3NlQh\|ryP	MXLTRW5ITVJ?
TGBC24TKB	M1XWPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHsVY5KSzVyPUCuNFQ4PjFizszN	MV3TRW5ITVJ?
A388	NG\RVZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MojNTWM2OD1yLkC1NFk2KM7:TR?=	MmK0V2FPT0WU
BB30-HNC	NUPwUHltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1OzUWlEPTB;MD6wOVQ{PyEQvF2=	NH;qXY9USU6JRWK=
GI-ME-N	NUDYbmpOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\Jd3FKSzVyPUCuNFYyOThizszN	M3r1cHNCVkeHUh?=
TGBC1TKB	NYrVdmFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTBwME[xOlQh\|ryP	M3TRdXNCVkeHUh?=
TE-10	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHQTWM2OD1yLkC2N\|U4KM7:TR?=	M1rpRnNCVkeHUh?=
A498	NEjVS5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUH4VWhLUUN3ME2wMlA4Ojh2IN88US=>	MnXTV2FPT0WU
TE-11	M2jPc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mkj6TWM2OD1yLkC3PFU5KM7:TR?=	MmnkV2FPT0WU
BB65-RCC	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1LyV2lEPTB;MD6wPFIzPyEQvF2=	NFnxTXhUSU6JRWK=
C2BBe1	M1LaZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGrZdZlKSzVyPUCuNFg{ODhizszN	NWf0[\|JiW0GQR1XS
NCI-H747	NUXscIUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTBwMEizOlIh\|ryP	NHT5OI9USU6JRWK=
IST-MES1	NGezboRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1npXGlEPTB;MD6wPFU2OiEQvF2=	NYTZZW9MW0GQR1XS
KALS-1	NGqxR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rsbmlEPTB;MD6wPVQ6KM7:TR?=	MWPTRW5ITVJ?
GCIY	NF;INVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\sbmlEPTB;MD6wPVY2PiEQvF2=	NF;N[Y9USU6JRWK=
RL95-2	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV:xeVhlUUN3ME2wMlExOzhizszN	M{LwZnNCVkeHUh?=
TE-1	M1rz[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTBwMUC1OEDPxE1?	NXXsZYZ4W0GQR1XS
NCI-H1355	MkfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnSRZlKSzVyPUCuNVExOjhizszN	NGH6VWZUSU6JRWK=
SW962	NFPnPVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnEZ\|JQUUN3ME2wMlEyOjl{IN88US=>	NGf5RW5USU6JRWK=
KLE	NIroW5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILDR4FKSzVyPUCuNVE{OTdizszN	MXfTRW5ITVJ?
MC116	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1:xXmlEPTB;MD6xNVQyKM7:TR?=	M1TPVHNCVkeHUh?=
NMC-G1	M3m5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TKPGlEPTB;MD6xNVYxPiEQvF2=	MWPTRW5ITVJ?
KU812	M2DqfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTBwMUG4PFMh\|ryP	NGTHcHhUSU6JRWK=
COLO-829	NXmzd3ZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3ftWGlEPTB;MD6xNlIyOyEQvF2=	M33WV3NCVkeHUh?=
NTERA-S-cl-D1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3SxTmlEPTB;MD6xNlI5OyEQvF2=	MWTTRW5ITVJ?
IST-MEL1	MlX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTBwMUO0OUDPxE1?	M1LGUnNCVkeHUh?=
MLMA	M3vy[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmjYTWM2OD1yLkG0NFMzKM7:TR?=	MkXlV2FPT0WU
LS-123	NID0RWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn3KTWM2OD1yLkG0NFY1KM7:TR?=	NE\zcJRUSU6JRWK=
LB2518-MEL	MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXxSJBKSzVyPUCuNVQyPjJizszN	Mle2V2FPT0WU
NB69	MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXKelNKSzVyPUCuNVQ1OzZizszN	Moi1V2FPT0WU
8-MG-BA	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHKTWM2OD1yLkG1OFU5KM7:TR?=	MUTTRW5ITVJ?
K5	MnzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUX4R5ZJUUN3ME2wMlE3PDh7IN88US=>	NX\zUYFPW0GQR1XS
KINGS-1	NInSNmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYrzUWx3UUN3ME2wMlE3PjZ4IN88US=>	NI\YU3NUSU6JRWK=
SF268	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfQepNjUUN3ME2wMlE4PDB2IN88US=>	NWnqNG9HW0GQR1XS
PF-382	Mmr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTBwMUe2O\|gh\|ryP	M3jBVHNCVkeHUh?=
SH-4	NVrYSIdCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEfZfY9KSzVyPUCuNVg1OTNizszN	M{D5OHNCVkeHUh?=
NALM-6	NYPNU4tYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWPVcnN6UUN3ME2wMlE6Ojl3IN88US=>	Ml7NV2FPT0WU
CP66-MEL	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkXNTWM2OD1yLkG5OVMyKM7:TR?=	M1joXnNCVkeHUh?=
697	M3vqeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{Dve2lEPTB;MD6xPVk5PyEQvF2=	NX25N2ZIW0GQR1XS
CP67-MEL	NV\SVlBiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWGxW41lUUN3ME2wMlIxPDh6IN88US=>	NVPHSI16W0GQR1XS
DSH1	M17MSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlzETWM2OD1yLkK0NFAyKM7:TR?=	NIHEPHBUSU6JRWK=
HCE-4	NGjxOHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXX2UHZ5UUN3ME2wMlI3PDN7IN88US=>	MnHsV2FPT0WU
MZ2-MEL	NFv2TnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjlTWM2OD1yLkK4OVM4KM7:TR?=	NFLxTohUSU6JRWK=
BL-41	Mm\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDVTWM2OD1yLkK5NVI{KM7:TR?=	NX3ZeFJZW0GQR1XS
HUTU-80	M3\GdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIm0RWlKSzVyPUCuN\|E1OiEQvF2=	MkPWV2FPT0WU
LOXIMVI	NEfldoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DUTGlEPTB;MD6zNVUxOyEQvF2=	MX3TRW5ITVJ?
no-10	NFTRfpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIG5XoFKSzVyPUCuN\|E6OzFizszN	MnO5V2FPT0WU
KARPAS-422	NHe2V2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1HqT2lEPTB;MD6zN\|k6PyEQvF2=	MXfTRW5ITVJ?
SW684	NH;NOnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MljOTWM2OD1yLkO0PVgh\|ryP	M1XV[nNCVkeHUh?=
SF126	MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1zsdWlEPTB;MD6zOVQyKM7:TR?=	M{PLdHNCVkeHUh?=
D-263MG	NUfIRVNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTBwM{[yNlQh\|ryP	NWPCNVIyW0GQR1XS
OVCAR-4	M4PNOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYewPVh4UUN3ME2wMlM4PDN\|IN88US=>	M{O0bXNCVkeHUh?=
BB49-HNC	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTBwM{i1PVkh\|ryP	NXjyPFBxW0GQR1XS
ONS-76	NEj4SplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVr6NI1KUUN3ME2wMlQzQTVzIN88US=>	NYr1do1PW0GQR1XS
MZ7-mel	NXnNTW1NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkKwTWM2OD1yLkS3PVEyKM7:TR?=	M2TBPXNCVkeHUh?=
RCC10RGB	MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PjZmlEPTB;MD60PVEyKM7:TR?=	M12zfnNCVkeHUh?=
BOKU	NYXKcJZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1HSeGlEPTB;MD60PVE{OyEQvF2=	MUHTRW5ITVJ?
no-11	NHTWO2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DKOWlEPTB;MD61NFIzQCEQvF2=	MVTTRW5ITVJ?
IST-SL2	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rIU2lEPTB;MD61NFMxOiEQvF2=	MVXTRW5ITVJ?
RKO	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTBwNUK5OlYh\|ryP	M322OXNCVkeHUh?=
HT-144	NFrwZXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2fvNWlEPTB;MD61N\|YxQSEQvF2=	MVvTRW5ITVJ?
NCI-H446	NF\KeJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEnMeIhKSzVyPUCuOlI4PiEQvF2=	M1fYbHNCVkeHUh?=
QIMR-WIL	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWD1NGU4UUN3ME2wMlcxPjJ7IN88US=>	Mlz5V2FPT0WU
MHH-PREB-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rtOmlEPTB;MD63OFQ3QSEQvF2=	MnzQV2FPT0WU
EW-16	NVTKUIN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTBwN{[xO\|gh\|ryP	MoH4V2FPT0WU
EW-24	M2TxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXjLbVhJUUN3ME2wMlc5OTZ3IN88US=>	Mo\SV2FPT0WU
LB373-MEL-D	Ml3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrKZVFKSzVyPUCuPFI2ODhizszN	M4m1SXNCVkeHUh?=
TE-9	NGPsdGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn3YTWM2OD1yLki3OVMzKM7:TR?=	NWjNNmp4W0GQR1XS
A3-KAW	NXGwdXd7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTBwOUi0OVIh\|ryP	NUDsfVV3W0GQR1XS
A101D	MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlHaTWM2OD1zLkCzNFQ{KM7:TR?=	NU[0VJNIW0GQR1XS
OCUB-M	NHTUTFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkTITWM2OD1zLkC0OFEzKM7:TR?=	Mo\5V2FPT0WU
ES4	NVK1ZoJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVnNbI1wUUN3ME2xMlA2OTR3IN88US=>	NGGzcXBUSU6JRWK=
TE-6	NYjRS284T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4TDbmlEPTB;MT6yNVIzPiEQvF2=	M{jze3NCVkeHUh?=
D-502MG	NVHGUmxUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnTe3NxUUN3ME2xMlI{Ozd4IN88US=>	NGjFfYhUSU6JRWK=
KNS-42	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkDaTWM2OD1zLkK0OFEzKM7:TR?=	NXnqd4lvW0GQR1XS
SNU-C2B	NYT5dFRsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYXleGZVUUN3ME2xMlMxPTh7IN88US=>	NYnH[2dsW0GQR1XS
NCI-H1838	Mlu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmK0TWM2OD1zLkOwO\|M{KM7:TR?=	MVjTRW5ITVJ?
NKM-1	NWHQcIVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTFwM{C4OVkh\|ryP	MnraV2FPT0WU
GI-1	MkL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\oTWlEPTB;MT6zOlIzKM7:TR?=	NGfqUYxUSU6JRWK=
NB5	NXj1bFFxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmTETWM2OD1zLkO5PFI4KM7:TR?=	NWjOc3k6W0GQR1XS
CAS-1	MoL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NILYT2xKSzVyPUGuOFA6QTJizszN	M2jZNXNCVkeHUh?=
HCE-T	NXv6OXZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXnUPWFKUUN3ME2xMlU3PzF2IN88US=>	M1L5THNCVkeHUh?=
SBC-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYfJR\|UxRTFwNUe5PFQh\|ryP	M1XKe3NCVkeHUh?=
JiyoyeP-2003	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmT0TWM2OD1zLkezOFY3KM7:TR?=	NHPQWVVUSU6JRWK=
TE-5	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3zIOGlEPTB;MT63PVE{QSEQvF2=	MX;TRW5ITVJ?
CAN	NYHKPGsyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPNdo5KSzVyPUGuPFIzPTJizszN	Mm\uV2FPT0WU
SK-UT-1	NVn0ZVI1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjtRoVKSzVyPUKuNVY3QTNizszN	M3v1WHNCVkeHUh?=
JVM-2	M2rwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DMbmlEPTB;Mj6zOlI5PCEQvF2=	Mlv5V2FPT0WU
LB771-HNC	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTJwNUe1OVEh\|ryP	M37SOXNCVkeHUh?=
NCCIT	M1G1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn31TWM2OD1{Lki2OlE3KM7:TR?=	M{X1PXNCVkeHUh?=
NCI-H2126	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXQN2tYUUN3ME2yMlg4PTV{IN88US=>	NWnBfoo3W0GQR1XS
Calu-6	NHrRSotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGTIV4hKSzVyPUOuNFU4PDFizszN	NEDLbnVUSU6JRWK=
SK-LMS-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTNwMUG4PFYh\|ryP	M2HSSnNCVkeHUh?=
ARH-77	NF3ZbZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGnZTJdKSzVyPUOuOFY6OTVizszN	NW\iOmZnW0GQR1XS
NB17	Ml3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIL3cIFKSzVyPUOuOlM5PDdizszN	MXPTRW5ITVJ?
A253	M4P6Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTNwN{OyOFYh\|ryP	MlrKV2FPT0WU
OPM-2	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLoTWM2OD12LkK3Olg2KM7:TR?=	M3;lfHNCVkeHUh?=
MV-4-11	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTRwM{[0OVQh\|ryP	MYHTRW5ITVJ?
SR	NFL0[4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGTHUY9KSzVyPUSuOFk6PTRizszN	M1OwfXNCVkeHUh?=
KG-1	MmC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTRwNkC4OFUh\|ryP	M3G1eXNCVkeHUh?=
OCI-AML2	NVrITJFFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M124emlEPTB;NT64OlE2PCEQvF2=	NVnPPHkzW0GQR1XS
D-247MG	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnfnTWM2OD14LkGyOVE6KM7:TR?=	MX\TRW5ITVJ?
DJM-1	NHW1cGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkD4TWM2OD14LkS4OVU5KM7:TR?=	MVXTRW5ITVJ?
RPMI-6666	M{fuW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYO0UlA5UUN3ME23MlI4ODZ5IN88US=>	MXPTRW5ITVJ?
KARPAS-45	NFW0SpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7KTWM2OD15LkWxOlcyKM7:TR?=	NG\tTpFUSU6JRWK=
LP-1	NUHtWIRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4nVN2lEPTB;Nz61OFc5OiEQvF2=	MkHjV2FPT0WU
RS4-11	NXLBOmtpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTdwNkW3PFch\|ryP	MXPTRW5ITVJ?
DU-4475	MnvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEHwb\|RKSzVyPUiuNlE3PTJizszN	M1TzRXNCVkeHUh?=
MONO-MAC-6	NVTzT5RMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmq4TWM2OD16LkK3NFY3KM7:TR?=	MW\TRW5ITVJ?
NCI-SNU-16	NFLkVHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRThwNU[xNlgh\|ryP	Ml3RV2FPT0WU
SJSA-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRThwN{K4NFUh\|ryP	NXTKdYM1W0GQR1XS
MMAC-SF	MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmXVTWM2OD16Lke5N\|A4KM7:TR?=	NUj4W2ZuW0GQR1XS
SK-NEP-1	M2jMdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRThwOEmxOVUh\|ryP	Mmf5V2FPT0WU
J-RT3-T3-5	M3T4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4\LVWlEPTB;OD65OlUzQSEQvF2=	MWPTRW5ITVJ?
SKM-1	M1PINWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYq0W\|lqUUN3ME25MlAyPzN2IN88US=>	M1X6eXNCVkeHUh?=
LB2241-RCC	NG\tSXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4TBW2lEPTB;OT6wNlAyOiEQvF2=	NUeyTVZvW0GQR1XS
SIG-M5	M4fDOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnrqTWM2OD17LkCyOFk{KM7:TR?=	MojHV2FPT0WU
EVSA-T	NYK5WnB7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPubmF1UUN3ME25MlI4Pzl\|IN88US=>	NHz0TldUSU6JRWK=
GT3TKB	NHTtUYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF:5fWxKSzVyPUmuN\|U2PDZizszN	Mnj3V2FPT0WU
NB6	NEDuWZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITMN49KSzVyPUmuPVIzPTlizszN	Mo\WV2FPT0WU
EHEB	NGfjSmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fVTGlEPTB;MUCuNFY2PiEQvF2=	M4\RbnNCVkeHUh?=
HEL	NXXqd\|NmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHIO\|dMUUN3ME2xNE41Pzd4IN88US=>	M3rHeXNCVkeHUh?=
ALL-PO	NW\NZ45tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXNTWM2OD1zMD63PVM5KM7:TR?=	NYHEbVQ3W0GQR1XS
TGW	M3fMdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTFzLkK4Nlgh\|ryP	MnLOV2FPT0WU
BC-3	MmDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PYWmlEPTB;MUKuNVE{QCEQvF2=	NUS3c4d6W0GQR1XS
IA-LM	NWDwcYw5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmnBTWM2OD1zMj60OFQ2KM7:TR?=	MlzKV2FPT0WU
UACC-257	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{DXeWlEPTB;MUKuPVE6QCEQvF2=	M1rv[3NCVkeHUh?=
KP-N-YS	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{HMOGlEPTB;MUKuPVI5OyEQvF2=	MmX1V2FPT0WU
Raji	MmHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHfEcIJKSzVyPUGzMlc1QTdizszN	MkfPV2FPT0WU
SF539	MlTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYjI[HJCUUN3ME2xN{45PTV5IN88US=>	NXy1b2J3W0GQR1XS
DMS-153	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmTYTWM2OD1zND6wNFI5KM7:TR?=	NEmzeJpUSU6JRWK=
L-540	NUPMcHFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIGwcGVKSzVyPUG1MlA3PzJizszN	NHf0TWxUSU6JRWK=
MN-60	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3HqWmlEPTB;MUWuNVk4QSEQvF2=	MXHTRW5ITVJ?
RPMI-8866	NGjTXnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPWR2FKSzVyPUG3MlQ1PTRizszN	NWPibmpyW0GQR1XS
NCI-H510A	NYDY[ZJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEW2XG5KSzVyPUG5MlM6PzNizszN	MWLTRW5ITVJ?
NB13	Ml;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoKxTWM2OD1zOT60PFc4KM7:TR?=	M{LnXnNCVkeHUh?=
HAL-01	Mo\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvOTWM2OD1zOT63OVQ{KM7:TR?=	MnHuV2FPT0WU
NCI-H720	M{PEe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXjJR\|UxRTJyLkK3N\|Mh\|ryP	MVTTRW5ITVJ?
REH	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF7FNHhKSzVyPUKwMlY{PTdizszN	Mni4V2FPT0WU
KNS-81-FD	MoHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHCTWM2OD1{Mz6xOFYh\|ryP	NXfYc4pPW0GQR1XS
HC-1	M3\4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rKcWlEPTB;MkSuOVU2OSEQvF2=	M{LPXHNCVkeHUh?=
NCI-H2141	MlPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnS4TWM2OD1{ND63O\|U1KM7:TR?=	NF\pWoJUSU6JRWK=
MOLT-4	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrmUIpKSzVyPUK2MlY4PTNizszN	NVXhSWJbW0GQR1XS
OMC-1	NYDGTGJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGPSdJhKSzVyPUK3MlE1OjJizszN	NIDpNHJUSU6JRWK=
LC-1F	NXXBc4R{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDBXmtMUUN3ME2yO{4{OjR3IN88US=>	MlPQV2FPT0WU
NCI-H1304	MmLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTJ6LkG2Nlgh\|ryP	MUnTRW5ITVJ?
BC-1	NIPrd41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnsN3FDUUN3ME2yPE43PTFizszN	M1X5cnNCVkeHUh?=
NCI-H64	NVHmNFFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoW3TWM2OD1{OT62NlU{KM7:TR?=	NULOTVBQW0GQR1XS
MOLT-16	NUG1V2JUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWLXfXJWUUN3ME2yPU43Ojl{IN88US=>	MVjTRW5ITVJ?
U-87-MG	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlTOTWM2OD1\|MD63OlYh\|ryP	NVPKbFlsW0GQR1XS
GAK	MmXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fjeGlEPTB;M{GuNlY5PiEQvF2=	NHzl[VhUSU6JRWK=
ES8	NU\5V41jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkexTWM2OD1\|Mj6xNlUzKM7:TR?=	MUDTRW5ITVJ?
HCC1599	NHXJfY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXnWe\|ZyUUN3ME2zNk4{OzJ3IN88US=>	MljEV2FPT0WU
EB-3	M{XheGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4nFVGlEPTB;M{SuN\|EyPyEQvF2=	NXjCeItvW0GQR1XS
HCC1187	NEXSO4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\ESXo2UUN3ME2zOU45ODV{IN88US=>	NI\TR5BUSU6JRWK=
SK-PN-DW	NG\TZVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mni5TWM2OD1\|Nj6xPVQ{KM7:TR?=	M2nicXNCVkeHUh?=
JVM-3	NVfq[WF6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkP0TWM2OD1\|Nz6yN\|M5KM7:TR?=	MlH5V2FPT0WU
HCC2157	NX6zN5NLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NInrVpdKSzVyPUO3Mlk6PDZizszN	M4XvWXNCVkeHUh?=
A4-Fuk	MljmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWS1fJNHUUN3ME2zPE4yODB7IN88US=>	NX7sfJFlW0GQR1XS
COR-L279	NGnyd\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGXp[VFKSzVyPUSwMlI5PTFizszN	MnjCV2FPT0WU
DEL	M{DBTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{nSR2lEPTB;NEGuPVA5PiEQvF2=	MXrTRW5ITVJ?
NCI-H1395	Moi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGS2[mJKSzVyPUSyMlAyPjNizszN	NFnrVXZUSU6JRWK=
MHH-NB-11	NUPkSppWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXezTJI3UUN3ME20N{4xQDF6IN88US=>	MUPTRW5ITVJ?
NCI-H2107	M3SyfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWGy[4h[UUN3ME20N{41QDR4IN88US=>	M4foUnNCVkeHUh?=
NEC8	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYfJR\|UxRTR2LkOzOkDPxE1?	M1q3fnNCVkeHUh?=
COLO-684	NWTuWFB5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrxTWM2OD12Nj6yNlU5KM7:TR?=	MUXTRW5ITVJ?
LS-411N	NGPi[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTR6LkS3OFgh\|ryP	MXzTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-c-Abl(Tyr245) / phospho-c-Src(Tyr416); PubMed: 23049975 PLoS One Protein levels of phosphorylated c-Abl (Tyr245), c-Abl, phosphorylated c-Src (Tyr416), c-Src, and GAPDH in NSC-34 cells overexpressing human wild-type or mutant SOD1s treated with various concentrations of dasatinib were measured by western blot. Cells were cultured in serum-free culture medium with doxycycline (Dox, 2 µg/ml), and western blot was performed at 24 h after dasatinib addition. p27 / p21; PubMed: 20145167 Clin Cancer Res Dasatnib induced cell cycle arrest. Dasatinib induced growth arrest, shown as a cell cycle distribution graph in the lower panel, correlated with increased p27 and p21 levels. Western blotting for levels of p27 and p21 was performed on protein lysates of THP-1 cells treated for 48 hours with indicated doses of dasatinib or DMSO. Detection of actin served as control for comparable protein loading. p-FAK / p-STAT3; PubMed: 23721490 BMC Cancer The effect of dasatinib in cell signalling. Western blot analysis with phosphorylated Src, FAK, Stat3, Akt and MAPK in HCC cell lines after 24 hours treatment of dasatinib. The cell lines were arranged according to their IC50 to dasatinib. The top three were most sensitive, the bottom 3 were least sensitive. cleaved caspase 3; PubMed: 20145167 Clin Cancer Res Dasatinib induced apoptosis. Dasatinib causes apoptosis in Mo7e-KitD816H cells as detected by cleavage of caspase 3. Whole cell lysates were prepared after 24 hour treatment with dasatinib. Caspase 3 and cleaved capase 3 were analyzed by western blotting. Actin serves as loading control.	23049975 20145167 23721490
Growth inhibition assay	IC50; PubMed: 23721490 BMC Cancer 9 HCC cell lines were exposed to the dedicated concentrations of dasatinib for 72 hours, and IC50 was tested by MTS. Results represent the mean (± SD) of three experiments.	23721490
Immunofluorescence	SRC / Met; PubMed: 26517812 Oncotarget Immunocytochemistry of SRC and Met localization. Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in A. LN-18 and B. U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively. F-actin / Actinin-4 / Paxillin; PubMed: 31053734 Nat Commun Conditionally immortalized differentiated podocytes treated for one-hour with 2 µM kinase inhibitor were stained for F-actin (phalloidin), α-actinin-4, paxillin, and nuclei (Hoechst 33342) to assess cytoskeletal and focal adhesion architecture (scale bars = 50 µm). Podocytes treated with dasatinib showed a marked decrease in cell-to-cell contacts, cell size and number of focal adhesions. α-tubulin; PubMed: 26517812 Oncotarget Combination of dasatinib and crizotinib impedes the formation of the α-tubulin-labeled mitotic spindle. LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.	26517812 31053734
ELISA	TNF-α; PubMed: 17684099 Proc Natl Acad Sci U S A U937 cells were differentiated with vitamin D3, pretreated with the indicated concentrations of drugs for 1 h and stimulated with LPS for 6 h. TNF-α secretion was measured by ELISA. The graph shows the mean of two experiments done in duplicate. E-selectin; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of E-selectin was determined using ELISA (n = 3, ±SEM). VCAM-1; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of VCAM-1 was determined using ELISA (n = 3, ±SEM).	17684099 31110200

体内研究

Dasatinib 作用于LMP2A/MYC 双转基因小鼠，可逆转脾肿大。Dasatinib 作用于TgE小鼠抑制表达LMP2A 的骨髓B 细胞形成的菌落，且使脾脏变小。使用Dasatinib处理Tg6/λ-MYC 小鼠，与对照组相比，脾脏质量明显降低。Dasatinib 作用于LMP2A/MYC 双转基因小鼠，抑制淋巴结肿大。Dasatinib作用于嫁接LMP2A/MYC双转基因小鼠肿瘤细胞的Rag1KO小鼠，可逆转脾肿大。Dasatinib 作用于表达LMP2A的B 淋巴细胞瘤，抑制Lyn磷酸化。^[2]

激酶实验：^[1]	- 合并激酶自磷酸化分析: 使用野生型和突变型谷胱甘肽S-转移酶(GST)-Abl融合蛋白 (c-Abl氨基酸220-498位) 进行激酶实验。从谷胱甘肽琼脂糖珠中释放GST-Abl融合蛋白，ATP浓度为5 μM。在用于激酶自磷酸化和体外肽底物磷酸化实验前, 用LAR酪氨酸磷酸酶处理GST-Abl 激酶域融合蛋白。在 30^oC下温育1小时后,加入1 mM 钒酸钠，激活LAR磷酸酶。进行免疫印迹分析，比较未处理的GST-Abl激酶和去磷酸化的GST-Abl激酶，使用磷酸化的特点抗体4G10来确认酪氨酸残基完全去磷酸化(>95%)，使用c-Abl抗体 CST 2862 来确认GST-Abl激酶的平衡负载。实验测定IC50值时所用Dasatinib浓度为0 nM到32 nM。Dasatinib作用于突变型T315I时浓度达到 1,000 nM。在体外肽底物磷酸化实验中使用相同抑制剂浓度。作用于GST-Src激酶和 GST-Lyn激酶的三种抑制剂的浓度范围相同。
细胞实验： ^[1]	- 合并 Cell lines: Ba/F3细胞系 Concentrations: 0 nM-32 nM Incubation Time: 72小时 Method: Ba/F3 细胞系重复培养三份，然后与浓度逐渐升高的 Dasatinib 温育72小时。通过MTS活性实验测定细胞增殖。IC50值和IC90值取自三组独立实验的平均值。Dasatinib作用的IC50值和IC90值为0 nM 到32 nM 。Dasatinib 作用于突变型T315I时所需浓度达到200 nM。 (Only for Reference)
动物实验：^[2]	- 合并 Animal Models: EμLMP2A(TgE 和Tg6品种),MYC (λ-MYC), 和LMP2A/λ-MYC双转基因小鼠(Tg6/λ-MYC) Formulation: DMSO Dosages: 30 mg/kg Administration: 腹腔注射 (Only for Reference)

参考文献

[4] Dargart JL, et al. Antiviral Res. 2012, 95(1), 49-56.

- 合并

溶解度 (25°C)

体外	DMSO	98 mg/mL (200.81 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 4% DMSO+30% PEG 300+5% Tween 80+ddH2O	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Dasatinib SDF

分子量	488.01
化学式	C₂₂H₂₆ClN₇O₂S
CAS号	302962-49-8
储存条件	3年 -20°C粉状
储存条件	2年 -80°C 溶于溶剂
别名	BMS-354825

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04063124	Not yet recruiting	Drug: Dasatinib + Quercetin	Alzheimer Disease	The University of Texas Health Science Center at San Antonio\|Mayo Clinic	December 2019	Phase 1\|Phase 2
NCT04115059	Not yet recruiting	Drug: Dasatinib	Waldenstrom Macroglobulinemia\|DASATINIB	Jorge J. Castillo MD\|Bristol-Myers Squibb\|Dana-Farber Cancer Institute	November 2019	Phase 1
NCT03318770	Not yet recruiting	Drug: Dasatinib and blinatumomab	Acute Lymphoblastic Leukemia	Gruppo Italiano Malattie EMatologiche dell''Adulto	December 2018	--
NCT03625388	Recruiting	Drug: Dasatinib	Chronic Myelogenous Leukemia	Hikma Pharmaceuticals LLC	November 5 2018	Phase 2
NCT03193281	Recruiting	Drug: Dasatinib\|Drug: Imatinib	Chronic Myeloid Leukemia	University of Auckland New Zealand\|Leukaemia & Blood Cancer New Zealand	July 17 2017	Phase 2
NCT03041701	Recruiting	Drug: Dasatinib\|Drug: Ganitumab	Rhabdomyosarcoma\|Rhabdomyosarcoma- Alveolar\|Rhabdomyosarcoma-Embryonal	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	July 7 2017	Phase 1\|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
what’s the difference between S1021 and S7782? Which one is better for in vivo studies?
回答：
Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).
问题 2：
Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?
回答：
Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

泛Src抑制剂

Saracatinib (AZD0530) : Pan-Src inhibitor, IC50=2.7-11 nM for c-Src/c-Yes/Fyn/Lyn/Blk/Fgr/Lck.
FDA批准的Src抑制剂

Bosutinib (SKI-606) : Approved by FDA for Ph+ chronic myelogenous leukemia (CML).
最新的Src抑制剂

PP1 : Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
经典的Src抑制剂

KX2-391 : The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

研究领域

产品类型

Dasatinib

客户使用Selleck该产品发表文献220篇：

产品安全说明书

Src抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Dasatinib SDF

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-10-14)

技术支持

常见问题及建议解决方法

Src Signaling Pathway Map

Src Inhibitors with Unique Features

相关Src产品